Table of Contents; High Content Screening: A Powerful Approach to Systems Cell Biology and Drug Discovery; Editors: D. Lansing Taylor1, Jeffrey R. Haskins2 and Kenneth A. Giuliano1; 1Cellumen, Inc. and 2Cellomics, Inc.; I. Introduction to High Content Screening; A. Past, Present and Future of HCS and the Field of Cellomics [Review Chapter]; D. Lansing Taylor; B. A Pharmaceutical Company User's Perspective on the Potential of High Content Screening (HCS) in Drug Discovery [Review Chapter]; Ann F. Hoffman, B.S. and Ralph J. Garippa; C. Linking Microscopy and High Content screening in Large-scale Biomedical Research [Review Chapter]; James G. Evans and Paul Matsudaira; II. Instrumentation, Biological Application Software, and Sample Preparation; A. Requirements, Features and Performance of High Content Screening Platforms [Review Chapter]; Albert H. Gough and Paul A. Johnston; B. Characteristics & Value of Directed Algorithms in HCS [Review Chapter]; Richik N. Ghosh, Oleg Lapets and Jeffrey R. Haskins; C. Characteristics and Value of Machine Learning for Imaging in HCS [Review Chapter]; Jurgen A. Klenk; D. Tools for Quantitative and Validated Measurements of Cells; Anne L. Plant, John T. Elliott, Alessandro Tona, Dennis McDaniel, and Kurt J. Langenbach; E. Automated Cell Plating and Sample Treatments for Fixed Cells in High Content Assays; Peter B. Simpson and Gillian R. Richards; F. Differentiating Primary Human Cells in Rapid-Throughput Discovery Applications; Daniel R. Marshak and Dale E. Greenwalt; G. Use of the CellCard[trademark] System for Analyzing Multiple Cell Types in Parallel; Oren Beske, Daniel Bassoni, and Simon Goldbard; III. Reagents; A. Reagents to measure and manipulate cell functions [Review Chapter]; Kenneth A. Giuliano, D. Lansing Taylor, and Alan S. Waggoner; B. Fluorescent Proteins and Engineered Cell Lines [Review Chapter]; Nick Thomas; C. Optimizing the integration of immunoreagents and fluorescent probes for multiplexed HCS assays; Kenneth A. Giuliano; D. The HaloTag[trademark]: A Novel Technology for Cell Imaging and Protein Analysis; Georgyi V. Los and Keith Wood; E. Protein labeling with FlAsH and ReAsH; Thomas Machleidt, Matt Roberts, and George Hanson. F. Exploiting Network Biology to Improve Drug Discovery [Review Chapter]; Marnie L. MacDonald and John K. Westwick; G. Physiological Indicators of Cell Function [Review Chapter]; Michael J. Ignatius and Jeffrey Hung; H. The Use of siRNA to Validate Immunofluorescence Studies; K. Gregory Moore, Wayne Speckmann, and Ron Herzig; I. Caged Substrates Applied to High Content Screening: An Introduction with an Eye to the Future; Peter G. Conrad, II, Rajesh V. Chavli, and Richard S. Givens; IV. Informatics and Bioinformatics; A. Overview of Informatics for HCS [Review Chapter]; R. Terry Dunlay, Wallace J. Czekalski, and Mark A. Collins; B. Large-Scale Data Management for High Content Screening [Review Chapter]; Leon S. Garfinkel; C. An Integrated Biomedical Knowledge Extraction and Analysis Platform: Using Federated Search and Document Clustering Technology; Donald P. Taylor; D. Visualization of High Content Screening Data [Review Chapter]; Matthew J. Anstett; E. Pathway Mapping Tools For Analysis of High Content Data [Review Chapter]; Sean Ekins, Yuri Nikolsky, Andre Bugrim, Eugene Kirillov, and Tatiana Nikolskaya; V. Assays and Applications of HCS; A. Systems Biology in Cancer Research: Genomics to Cellomics; Jackie L. Stilwell, Yinghui Guan, Richard M. Neve, and Joe W. Gray; B. Target Validation in Drug Discovery; Robert A. Blake; C. HCS as a Screening Tool in Drug Discovery; Anthony Nichols; D. Discovery of Protein Kinase Phosphatase Inhibitors; Andreas Vogt and John S. Lazo; E. High Content Translocation Assays for Pathway Profiling [Review Chapter]; Frosty Loechel, Sara Bjorn, Viggo Linde, Morten Praestegaard, and Len Pagliaro; F. In vitro Cytotoxicity Assessment [Review Chapter]; Peter O'Brien and Jeffrey R. Haskins; G. Neurite Outgrowth in Retinal Ganglion Cell Culture; John B. Kerrison and Donald J. Zack.